

**3.3 billion** people at risk

Low-economy countries



# Children and women

disproportionately affected

#### Resistance

to current interventions



# MMV strategic priorities 2015-2018

from control to eradication

2015 2016-2018 2018+

Maximize
health impact
of launched
antimalarial
medicines

Introduce better medicines
to enhance malaria control and reduce morbidity/mortality

cures
to facilitate
elimination
& eradication



# 376 partners spanning the world



### including:

28 pharmaceuticals companies

13 biotech companies

56 universities

38 research institutes

72 clinical sites

50 government agencies



# 5 (+2) medicines launched from 2009-2015


















### **SERCaP**



single encounter radical cure and prophylaxis



#### 9 new medicines

#### in clinical development

Pyramax-granules (Filed)

Eurartesim-dispersible (Phase III)

Rectal artesunate (Phase IIIb)

Tafenoquine (Phase III)

OZ439/PQP (Phase IIb)

KAE609 (Phase IIa)

KAF156 (Phase IIa)

DSM265 (Phase IIa)

MMV048 (Phase I)



# **Novel chemotypes and new targets**

Chemotype and related series	Biological Target	Number of molecules
4-aminoquinolines	Active against CQ-resistant malaria	1 (FQ)
Semi- or fully synthetic peroxides	Active against ART resistance	1 (OZ439)
Diaminopyrimidine	Active against all DHFR resistance	1 (P218)
8-aminoquinoline	Unknown	1 (tafenoquine – single dose)* studies in C21st!
Multiple diverse series	New - ATP4	4 (KAE609, SJ733, GSK030, PA92)
Triazolopyrimidine	New – DHODH	1 (DSM265)
Aminopyridine	New - PI4K	1 (MMV048)
Quinoline	New - to be disclosed	1 (MMV121)
Triaminopyrimidine	New - V-type H+ ATPase	1 (MMV243)
Quinolone	New – bc1 Qi inhibitor	1 (ELQ-300)

New modes of action, overcome historical resistance or single dose



# MMV supported projects 1Q 2015


#### **Translational APM** Research **Development Patient** Under review \* Lead **Preclinical** Human **Patient** Post optimization approval \* volunteers exploratory confirmatory MMV048 **Tafenoquine** Artemether-**Novartis** Novartis P218 DHFR OZ439/PQP Rectal lumefantrine Artesunate Univ. Cape Town/ Miniportfolio 1 project Biotec/ (Monash Univ./ GSK Sanofi dispersible Technology Innovation Cipia/ Strides/ WHO-TDR London School of Hygiene Agency Novartis & Trop Med) SJ733 Pyronaridine-GSK GSK OZ439/FQ Dihydroartemisinin-Artesunate artesunate pipéraquine paediatric National Institutes Sanofi for injection Miniportfolio 3 projects paediatric of Health (NIH)/ Guilin Sigma-Tau Shin Poong/ Univ. Iowa (St Jude/Rutgers Univ.) Sanofi **AstraZeneca DDD498 KAE609** Dihydro-Orthologue Leads Merck Serono/ Novartis artémisinin-Miniportfolio piperaquine (Univ. Dundee) Sigma-Tau **KAF156** Celgene Anacor PA92 (Drexel Univ./ Univ. Pyronaridineartesunate Heterocycles Oxaboroles **Novartis** Washington/ Genomics Shin Poong Institute of the Novartis Research Foundation) Liverpool School of Trop Med/ Univ. Campinas Artesunate-MMV253 DSM265 amodiaquine Heterocycles (AstraZeneca) Takeda/ NIH Univ. Liverpool Sanofi/ DND/ Tetraoxanes Daiichi-Sanyko Univ. of Texas South-Artesunate-**GSK030** western/Monash Univ./ mefloquine Screening GSK Univ. of Washington/ Cipla/ DND/ DHODH Takeda Univ. Cape Town SP+AQ Screening Aminopyridines (Sulfadoxine-Pyrimethamine + Amodiaquine) Gullin Eisai Univ. Sydney Screening Open Source Drug Discovery MMV Merck Serono Pathogen Box Amino-alcohols

Other projects 15 projects



# MMV strategic framework to 2018

# portfolio | pipeline





# MMV is grateful for the support of the following donors

















